Despite FDA Doubts, Adcomm Backs Alnylam's Gene Silencing Therapy For Expanded Use Into Rare Heart Disease
Portfolio Pulse from Vandana Singh
An FDA advisory committee has voted in favor of Alnylam Pharmaceuticals' patisiran for use in cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis, despite earlier doubts raised by FDA staffers. This could potentially challenge Pfizer's market dominance with tafamidis in treating ATTR-CM. Alnylam's shares are up 4.80% premarket.
September 14, 2023 | 11:26 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Pfizer's market dominance with tafamidis in treating ATTR-CM could potentially be challenged by Alnylam's patisiran, which has received backing from an FDA advisory committee.
The FDA committee's backing of Alnylam's patisiran for use in ATTR amyloidosis could potentially challenge Pfizer's market dominance with tafamidis in treating ATTR-CM. This could lead to a decrease in revenues for Pfizer in this area, which could negatively impact the company's stock price.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 70
POSITIVE IMPACT
Alnylam's patisiran received backing from an FDA advisory committee for use in ATTR amyloidosis, potentially challenging Pfizer's market dominance. This news has led to a 4.80% premarket increase in Alnylam's shares.
The FDA committee's backing of Alnylam's patisiran for use in ATTR amyloidosis is a positive development for the company. This could potentially challenge Pfizer's market dominance in this area, which could lead to increased revenues for Alnylam. The news has already had a positive impact on Alnylam's stock price, with shares up 4.80% premarket.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100